Trial reportAnnals of medicine2025
Effect of different doses of intravenous dexmedetomidine as an adjunct to the serratus anterior plane block in patients undergoing modified radical mastectomy: a randomized controlled trial.
Trial report in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to observe the effect of different doses of intravenous dexmedetomidine as an adjunct to the serratus anterior plane block (SAPB) on postoperative analgesia in patients undergoing modified radical mastectomy. PATIENTS AND
methodsEighty-five patients scheduled for modified radical mastectomy were recruited and randomly divided into R, RD 0.5, and RD 1.0 groups. All three groups underwent preoperative SAPB. During surgery, intravenous infusion of saline (50 mL) or saline with dexmedetomidine (50 mL) was administered (no dexmedetomidine in Group R, 0.5 μg/kg dexmedetomidine in Group RD 0.5, and 1.0 μg/kg dexmedetomidine in Group RD 1.0). The primary outcome of the trial was the area under the curve (AUC) of the Numerical Rating Scale (NRS) pain intensity scores upon movement within 24 h. Secondary outcomes included the AUC of the NRS pain intensity scores at rest within 24 h, postoperative oral morphine equivalents (OME), Quality of Recovery-15 (QoR-15), and incidence of adverse events.
resultsAt rest and upon movement, the 24-h AUC of NRS pain scores in the RD 1.0 group was significantly lower than that in the R group (
conclusionAdministration of 1.0 µg/kg intravenous dexmedetomidine as an adjunct to SAPB significantly reduces the postoperative pain intensity in patients undergoing modified radical mastectomy and decreases the postoperative consumption of analgesics.
trial registrationThe trial was registered at the Chinese Clinical Trial Registry (ChiCTR2300071444, date of registration: May 16, 2023); pre-results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.